CN101711255A - 具有改变的电子传递途径的修饰珠蛋白 - Google Patents

具有改变的电子传递途径的修饰珠蛋白 Download PDF

Info

Publication number
CN101711255A
CN101711255A CN200880021531A CN200880021531A CN101711255A CN 101711255 A CN101711255 A CN 101711255A CN 200880021531 A CN200880021531 A CN 200880021531A CN 200880021531 A CN200880021531 A CN 200880021531A CN 101711255 A CN101711255 A CN 101711255A
Authority
CN
China
Prior art keywords
albumen
iron
leu
oxyphorase
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880021531A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托夫·埃里克·库珀
米歇尔·托马斯·威尔逊
布兰东·乔恩·里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Essex Enterprises Ltd
Original Assignee
University of Essex Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Essex Enterprises Ltd filed Critical University of Essex Enterprises Ltd
Publication of CN101711255A publication Critical patent/CN101711255A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200880021531A 2007-06-29 2008-06-26 具有改变的电子传递途径的修饰珠蛋白 Pending CN101711255A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0712685.7A GB0712685D0 (en) 2007-06-29 2007-06-29 Improvements relating to oxygen-carrying proteins (2)
GB0712685.7 2007-06-29
PCT/GB2008/002199 WO2009004309A1 (en) 2007-06-29 2008-06-26 Modified globin proteins with altered electron transport pathway

Publications (1)

Publication Number Publication Date
CN101711255A true CN101711255A (zh) 2010-05-19

Family

ID=38420974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880021531A Pending CN101711255A (zh) 2007-06-29 2008-06-26 具有改变的电子传递途径的修饰珠蛋白

Country Status (9)

Country Link
US (1) US8609814B2 (enExample)
EP (1) EP2170948B1 (enExample)
JP (1) JP2010531659A (enExample)
CN (1) CN101711255A (enExample)
AU (1) AU2008272721B2 (enExample)
BR (1) BRPI0812403B8 (enExample)
CA (1) CA2690370A1 (enExample)
GB (1) GB0712685D0 (enExample)
WO (1) WO2009004309A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2858495A4 (en) 2012-04-30 2016-06-01 Dow Agrosciences Llc VEHICLES FOR RELEASING PESTICIDE COMPOSITIONS
GB201704006D0 (en) * 2017-03-13 2017-04-26 Univ Essex Modified globin proteins
JP7387597B2 (ja) 2017-07-18 2023-11-28 ヴァーテック・バイオ・インコーポレイテッド ヘモグロビンを含む代用血液及び作製方法
GB201721503D0 (en) * 2017-12-20 2018-01-31 Univ Essex Modified globin proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8711614D0 (en) * 1987-05-16 1987-06-24 Medical Res Council Proteins
US5884323A (en) * 1995-10-13 1999-03-16 3Com Corporation Extendible method and apparatus for synchronizing files on two different computer systems
EP0859789A1 (en) 1995-10-23 1998-08-26 Rice University Hemoglobin mutants that reduce heme loss
GB0712683D0 (en) 2007-06-29 2007-08-08 Wivenhoe Technology Ltd Improvements relating to oxygen-carrying proteins(1)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NIELS B.J. VOLLAARDA,ET AL: "A new sensitive assay reveals that hemoglobin is oxidatively modified in vivo", 《FREE RADICAL BIOLOGY & MEDICINE》 *
VE´RONIQUE BAUDIN-CREUZA,ET AL: "Additive Effects of b Chain Mutations in Low Oxygen Affinity Hemoglobin bF41Y,K66T", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Also Published As

Publication number Publication date
EP2170948A1 (en) 2010-04-07
WO2009004309A1 (en) 2009-01-08
CA2690370A1 (en) 2009-01-08
AU2008272721A1 (en) 2009-01-08
US8609814B2 (en) 2013-12-17
BRPI0812403A2 (pt) 2014-12-02
GB0712685D0 (en) 2007-08-08
JP2010531659A (ja) 2010-09-30
BRPI0812403B8 (pt) 2021-05-25
AU2008272721B2 (en) 2013-06-27
BRPI0812403B1 (pt) 2019-08-27
EP2170948B1 (en) 2016-11-02
US20100137189A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
US5948609A (en) Oxygen-transporting albumin-based blood replacement composition and blood volume expander
PT85133B (pt) Processo para a preparacao de hemoglobina
AU671728B2 (en) Methods of production of analogues of human Cu/Zn superoxide dismutase
Bobofchak et al. A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O2 transporter
Tamburrini et al. The amino acid sequence and oxygen-binding properties of the single hemoglobin of the cold-adapted Antarctic teleost Gymnodraco acuticeps
CN101711255A (zh) 具有改变的电子传递途径的修饰珠蛋白
FI104722B (fi) Pyridoksiloidun hemoglobiinin valmistusmenetelmä
AU685661B2 (en) Human serum albumin-porphyrin complexes with the ability to bind oxygen and therapeutic uses thereof
CA1340597C (en) Expression vectors containing pl promoter, and engineered restriction site for convenient replacement of ribosomal binding site, plasmids containing the vectors, hosts containing the plasmids and related methods
CA2072081C (en) Polyhemoglobin stabilized by purine derivatives and glutathione
WO1994014471A1 (en) Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
US12180266B2 (en) Modified haemoglobin proteins
US7329641B2 (en) Blood substitutes
CA2366833C (en) Hemoglobin-antioxidant conjugates
CN103966156A (zh) 一种应用于胰岛移植中胰岛分离提纯的分离纯化液及其制备方法
US5334705A (en) Benzenetricarboxylate derivative-crosslinked low oxygen affinity hemoglobin
US6180598B1 (en) Covalently modified hemoglobin having low temperature-dependent oxygen-binding function
JPS62226928A (ja) 臓器機能改善剤
CA2170638A1 (en) Improvements in or relating to haemoglobin
CA3113147A1 (en) Recombinant hemoglobins and methods of preparation and use thereof
Atassi et al. Oxygen-binding heme complexes of peptides designed to mimic the heme environment of myoglobin and hemoglobin
US20250186381A1 (en) Artificial oxygen carrier blood product
AU715902B2 (en) Purification of hemoglobin
WO2009004310A1 (en) Modified globin proteins with attenuated electron transport pathway
Manning Design of chemically modified and recombinant hemoglobins as potential red cell substitutes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Essex

Applicant after: University of Essex Industries Ltd

Address before: Essex

Applicant before: Wivenhoe Technology Ltd.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: WIVENHOE TECHNOLOGY LTD. TO: UNIVERSITY OF ESSEX INDUSTRY CO., LTD.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100519